Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Diagnosis & Disease Information
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Texas-Mexico Border Residence Linked to Worse Survival in Children With ALL
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Chest CT Prior to Allo-HSCT Deemed Beneficial for Spotting Abnormalities
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
Comorbidity Burden Predicts Survival in Acute Promyelocytic Leukemia
Comorbidity burden is an independent predictor of survival in older patients with acute promyelocytic leukemia.
ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Patient-Centered Communication Tool Feasible for Seniors With AML
Patients and caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Rezlidhia Now Available for Relapsed/Refractory AML With IDH1 Mutation
Rezlidhia (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...